C-Type Lectin Domain Family 9 Member A (CLEC9A) Antibody (APC)

Este producto es parte de CLEC9A - C-type lectin domain containing 9A
Product Graph
429€ (100 tests)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
C-Type Lectin Domain Family 9 Member A (CLEC9A) Antibody (APC)
category
Primary Antibodies
provider
Abbexa
reference
abx347139
tested applications
FCM

Description

C-Type Lectin Domain Family 9 Member A (CLEC9A) Antibody is a Mouse Monoclonal against C-Type Lectin Domain Family 9 Member A (CLEC9A).

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
C-Type Lectin Domain Family 9 Member A (CLEC9A)
Host
Mouse
Reactivity
Human
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Clonality
Monoclonal
Conjugation
APC
Isotype
IgG2a
Clone ID
D178
Size 1
100 tests
Tested Applications
FCM
Buffer
Stabilizing PBS solution containing 15 mM sodium azide.
Availability
Shipped within 5-12 working days.
Storage
Store in the dark at 2-8°C. Avoid exposure to light. Do not freeze.
Dry Ice
No
UniProt ID
Q6UXN8
Gene ID
283420
Alias
CD370,DNGR1,DNGR-1,
Background
Antibody anti-CLEC9A
Status
RUO

Descripción

CLEC9A, also known as C-type lectin domain family 9 member A or DNGR-1 (Dendritic Cell Natural Killer Lectin Group Receptor 1), is an immune receptor primarily expressed on a subset of dendritic cells (DCs) and certain populations of macrophages. CLEC9A is part of the C-type lectin receptor (CLR) family, which is known for its role in recognizing carbohydrate structures on pathogens, triggering immune responses, and presenting antigens to T cells. However, CLEC9A is unique within this family for its specialized function in detecting necrotic cells and facilitating the cross-presentation of antigens from dead cells. This capability enables CLEC9A to bridge innate and adaptive immunity, playing a significant role in immune responses to infections, cancer, and tissue injury.The receptor's ability to recognize damaged cells, rather than simply pathogens, underscores its importance in contexts such as infection, cancer immunology, and autoimmunity. CLEC9A has therefore gained interest for its potential applications in vaccine development and immunotherapy. Its expression is mainly restricted to CD8+ DCs and their human equivalent, BDCA3+ DCs, which are specialized for cross-presentation, making CLEC9A a critical component in inducing CD8+ T cell responses.

Related Products

FNab01758

CLEC9A antibody

Functions as an endocytic receptor on a small subset of myeloid cells specialized for the uptake and processing of material from dead cells. Recognizes filamentous form of actin in association with particular actin-binding domains of cytoskeletal proteins, including spectrin, exposed when cell membranes are damaged, and mediate the cross-presentation of dead-cell associated antigens in a Syk-dependent manner.

Ver Producto
P0679

Recombinant Human CLEC9A

Ver Producto
abx029711

C-Type Lectin Domain Family 9 Member A (CLEC9A) Antibody

CLEC9A is a group V C-type lectin-like receptor (CTLR) that functions as an activation receptor and is expressed on myeloid lineage cells (Huysamen et al., 2008 [PubMed 18408006]).

Ver Producto